Navigation Links
Isis Pharmaceuticals to Present at the 2010 Citi Investment Research Global Health Care Conference

CARLSBAD, Calif., May 21 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Citi Investment Research's 2010 Global Health Care Conference on Thursday, May 27, 2010 at 2:30 p.m. ET at the New York Hilton Hotel.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site,  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.


Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 46th American Society of Clinical Oncology Annual Meeting
2. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
3. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 107th China Import and Export Fair
4. WellPoint Is First Health Benefits Company to Release CER Guidelines for Use in Evaluating Pharmaceuticals
5. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
6. Isis Pharmaceuticals to Discuss Its Cancer Franchise in a Conference Call on Wednesday, May 19
7. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
8. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
9. Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010
10. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
11. DUSA Pharmaceuticals Announces Slate of Nominees for Election to the Board of Directors
Post Your Comments:
(Date:11/24/2015)... Nueva York , 24 de noviembre ... fabricante del Avery Breathing Pacemaker System, se complace ... MD; Ph.D. como consultor clínico. ... --> Foto -   ... doctor Jonzon es un fisiólogo y consultor en ...
(Date:11/24/2015)... 24, 2015 Avery Biomedical Devices (ABD), manufacturer ... announce the appointment of Anders Jonzon , MD; ... Dr. Jonzon is a Physiologist ... Hospital, Uppsala University, Uppsala and Children,s Hospital, Karolinska, ... a fellow at the Cardiovascular Institute (UCSF). His research ...
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a noted general ... of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many ... the doctor uses other traditional cutting tools, such as the scalpel and high-speed drill, ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article published November 12th ... which patients are or are not eligible for bariatric surgery. The article explains that ... are more than 100 pounds overweight, or have a BMI of 35 and over ...
(Date:11/24/2015)... ... 2015 , ... It takes only three to five seconds to make a ... first impression be positive and reflects business values. If a client starts with a ... to return. They will also share their thoughts about a business with others, which ...
(Date:11/24/2015)... ... 2015 , ... Cancer patients, survivors, caregivers, family members and ... taping of the next CURE Connections® video series on Saturday, Dec. ... at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE Connections, ...
(Date:11/24/2015)... Danbury, CT (PRWEB) , ... November 24, 2015 , ... ... Network (WCHN) today announced an innovative study designed to yield insights into how to ... potential development of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic ...
Breaking Medicine News(10 mins):